Fu Ying, Li Jun, Feng Ming-Xuan, Yang Xiao-Mei, Wang Ya-Hui, Zhang Yan-Li, Qin Wenxin, Xia Qiang, Zhang Zhi-Gang
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2123-32. eCollection 2014.
Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality, and is characterized by high potential for metastasis and recurrence. The outcome of it is still poor due to lacking of targeted therapeutic strategies. There is an urgent need to find new therapeutic targets for interventions against HCC metastasis and recurrence. In the present study, we found cytohesin-3, a member of the cytohesin family, was upregulated in HCC tissues, and its expression was negatively correlated with the overall survival and relapse-free survival of HCC patients. Further clinicopathological correlation analysis revealed that cytohesin-3 expression was related with tumor size and vascular invasion. And in vitro studies revealed that knock-down of cytohesin-3 suppressed HCC cells proliferation and migration. These results suggest that cytohesin-3 may act as a novel prognostic factor of HCC, and it might also be useful to exploit targeted therapeutic drugs against HCC growth and metastasis.
肝细胞癌（HCC）是一种发病率和死亡率都很高的恶性肿瘤，其特点是转移和复发的可能性很大。由于缺乏靶向治疗策略，其治疗效果仍然很差。迫切需要找到新的治疗靶点来干预HCC的转移和复发。在本研究中，我们发现细胞粘附分子3（cytohesin-3），细胞粘附分子家族的一员，在HCC组织中上调，其表达与HCC患者的总生存期和无复发生存期呈负相关。进一步的临床病理相关性分析显示，细胞粘附分子3的表达与肿瘤大小和血管侵犯有关。体外研究表明，敲低细胞粘附分子3可抑制HCC细胞的增殖和迁移。这些结果表明，细胞粘附分子3可能作为HCC的一种新的预后因素，开发针对HCC生长和转移的靶向治疗药物可能也有用。
